FDA gains power to demand food recipes, hidden ingredients from manufacturers
H.R. 8432 — To provide the Food and Drug Administration needed authorities to carry out its regulatory mission with respect to human foods, to provide additional resources and authorities with respect to human foods research, and for other purposes. · Filed by Diana DeGette (D-CO) · 1 cosponsor · Introduced Apr 22, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill expands FDA authority and resources to regulate human foods more comprehensively. It establishes a research grant program for food safety and nutrition, creates an advisory committee on food science, requires food manufacturers to disclose hidden ingredients and recipe details to the FDA, and sets up a public-private partnership to study chemicals in food packaging. The bill funds innovation in food biotechnology, infant nutrition, and the health impacts of ultra-processed foods.
Why we flagged it
The bill's core mechanism is regulatory empowerment: it grants the FDA new disclosure authorities, research capacity, and advisory infrastructure to strengthen food safety oversight and transparency. The operative provisions (Sections 7–8) mandate manufacturer disclosure and establish public-private information sharing, not deregulation or industry carve-outs.
What the text implies
- Section 7's requirement that manufacturers disclose 'nonlabeled ingredients' (flavors, colors, spices, incidental additives) and submit them to the FDA for public listing may expose proprietary formulations; manufacturers may argue trade-secret protection, creating litigation risk and potential regulatory delays.
- Section 8's public-private partnership on food-contact chemicals gives nongovernmental entities (likely industry groups) a formal advisory role in recommending chemical limits; the partnership's composition and voting structure are not specified, creating potential for industry capture of safety standard-setting.
- The 'Sense of Congress' on a Human Foods Innovation Account (Section 2) does not mandate appropriations; actual funding depends on future budget action, so the bill's stated activities may remain unfunded aspirations.
- Section 6's Paperwork Reduction Act exemption for FDA research removes a procedural check on information collection; while intended to streamline research, it eliminates public notice-and-comment requirements for voluntary data collection, reducing transparency in FDA research design.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Citizens gain transparency into food composition (hidden ingredients must be disclosed), stronger FDA oversight capacity through research and advisory infrastructure, and evidence-based policy on food safety and nutrition. Manufacturers face compliance costs, but these are passed through normal market channels and do not restrict citizens' access to food or information.
Who stands to gain
- nonprofit research institutions (eligible for critical research grants)
- academic medical centers (collaboration partners in grant programs)
- food biotechnology firms (research focus areas)
- food industry associations (public-private partnership participants)
Named in the bill
Food and Drug Administration (FDA), Department of Health and Human Services (HHS), Center for Drug Evaluation and Research (CDER), National Institutes of Health (NIH), Advisory Committee on Human Foods, Human Foods Program, Food and Drug Omnibus Reform Act of 2022
Where it stands
1 cosponsor: 1 Democrats.
- Apr 22, 2026 — Introduced · Congress.gov: “Introduced in House”
- Apr 22, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $30,000 in lobbying spend. A filing names 27 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
Diana DeGette, the sponsor, reported $915,500 in PAC receipts in the 2026 cycle.
- Mondelez International, Inc. — $30,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (8,686 characters) on Jun 3, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“FDA gains power to demand food recipes, hidden ingredients from manufacturers” QuorumCivic. https://share.quorumcivic.app/bill/119/hr8432 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.